Golotimod hydrochloride (SCV 07 hydrochloride) is an immunomodulating peptide with antimicrobial properties. It enhances antituberculosis therapy effectiveness, promotes thymic and splenic cell proliferation, and boosts macrophage functionality. Furthermore, it inhibits STAT3 signaling, thereby modifying the duration and intensity of oral mucositis in animal models subjected to radiation or a combination of radiation and Cisplatin. Additionally, Golotimod hydrochloride has shown potential as a treatment for recurrent genital herpes simplex virus type 2 (HSV-2) [1] [2] [3].

Golotimod hydrochloride is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) [1]. Golotimod inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin [2].